Novo Nordisk weight-loss drug probed for side-effects

Weight-loss medications from Novo Nordisk are being investigated by the EU’s drugs regulator after several reports of suicidal risks were referred to the watchdog.

The European Medicines Agency (EMA) is looking at adverse events noted by the Icelandic Medicines Agency, including two cases of suicidal thoughts linked to the drugs Saxenda and Ozempic, the EMA said in a statement Monday. One additional case relating to thoughts of self-injury has been raised in connection with Saxenda…